Disulfiram for Cocaine-Alcohol Abuse - 3 - Full Text View

Disulfiram for Cocaine-Alcohol Abuse - 3

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) VA Connecticut Healthcare System
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000278

Purpose

The purpose of this study is to evaluate disulfiram for cocaine-alcohol abuse.

Condition	Intervention	Phase
Alcohol-Related Disorders Cocaine-Related Disorders	Drug: Disulfiram	Phase II

Drug Information available for:

Disulfiram 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- Cocaine hydrochloride Ethanol

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Official Title:	Disulfiram for Cocaine-Alcohol Abuse

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Estimated Enrollment:

Eligibility

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000278

Locations


United States, Connecticut
	VA Connecticut Healthcare System
	New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

VA Connecticut Healthcare System

Investigators


Principal Investigator:	Thomas R Kosten, M.D.	VA Connecticut Healthcare System

More Information

Study ID Numbers:	NIDA-09250-3, P50-09250-3
First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000278
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Disulfiram

Cocaine-Related Disorders

Mental Disorders

Alcoholism

Substance-Related Disorders

Disorders of Environmental Origin

Alcohol-Related Disorders

Cocaine

Ethanol

Additional relevant MeSH terms:

Pathologic Processes

Disease

Molecular Mechanisms of Pharmacological Action

Therapeutic Uses

Enzyme Inhibitors

Central Nervous System Agents

Pharmacologic Actions

Alcohol Deterrents

ClinicalTrials.gov processed this record on December 03, 2008